Surgery Websites
Resident Research »  Leadership »  Research Committee Members »  Gillian L Hirst, PhD
Gillian L Hirst, PhD

Gillian L Hirst, PhD

Assistant Professor
Division of Surgical Oncology
Administrative Director
T32 Training Grant in Surgical Oncology



Contact Information

Open Popup

University of Newcastle-upon Tyne, UK, BSc (Hons) Physiological Sciences 1991

University of Edinburgh, PhD. Molecular Oncology, 1995

  • University of Glasgow, UK, Molecular Oncology, 1995 - 2000
  • University of California, San Francisco, Genetics, Oncology 2000-2003
  • Biomarkers
  • Breast Cancer
  • Carcinogenesis
  • Drug Resistance
  • Genetic Risk
  • Precision Medicine
  • Tumor Biology

Gillian Hirst received her Ph.D. at the University of Edinburgh in the ICRF's (now CRUK) Molecular Oncology Unit, where she focused on the analysis and development of estrogen-regulated biomarkers for use in ovarian and breast cancers treated with anti-estrogenic therapies. As a postdoctoral fellow at CRUK Beatson Laboratories, University of Glasgow, she studied the molecular mechanisms of cisplatin resistance in ovarian cancer, with emphasis on the mismatch repair pathway. Building upon this work she studied the genetic susceptibility to DNA damaging agents in Allan Balmain's group here at UCSF. She has over ten years' experience working as a scientific program manager for multi-consortia projects and oversees biomarker development for the I-SPY2 TRIAL for early high-risk breast cancer, as well as multiple research initiatives within the Breast Care Center and the NIH Molecular Characterization of Screen-detected Lesions Consortium.

Dr. Hirst's areas of research interest span the continuum of disease risk in the analysis and development of biomarkers which will lead to better patient stratification and refined treatment interventions.

  Award  
  Confired By    
  Date    
  • CRC Post-Doctoral Fellowship
  • Beatson Institute, University of Glasgow
  • 1993 - 1999
  • Dr Hirst has over 15 years of research experience and managing scientific research programs. Her research interest particularly focuses on the molecular genetics of carcinogenesis, particularly as it relates to breast and ovarian cancer and understanding how we can better utilize biomarkers for risk stratification and treatment refinement. As Scientific Program Manager in the I-SPY2 TRIAL she oversees biomarker development and works with investigators from both academia and pharma to analyze data, tumor and liquid biopsy specimen using expression arrays, next-gen sequencing, multiplex-IHC and phospho-protein arrays.

    As an investigator on a U01 which is part of the NIH Molecular Characterization of Screen-Detected Lesions (MCL) consortium, her research is focused on building tissue, pathology and imaging resources to assist in the better molecular definition of DCIS and defining who will recur with aggressive invasive cancer or not. The hope is to be able to stratify patients for either less treatment intervention or more at the earliest stages of disease, and to find potentially common drivers of aggressive disease across multiple disease types, as well as markers of indolent disease by looking at both tumor and stromal microenvironment biology.

    Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0002-4502-0035 Additional info
    • Surgical Oncology Training Grant
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jul 2020
      -
      Jun 2025
      Administrative Director
    • I-SPY2 +: Evolving the I-SPY 2 TRIAL to include MRI-directed, adaptive sequential treatment to optimize breast cancer outcomes
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2017
      -
      Aug 2022
      Co-Investigator
    • Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2015
      -
      Aug 2020
      Co-Investigator
    • Modeling the Impact of Targeted Therapy Based on Breast Cancer Subtypes
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2014
      -
      Aug 2019
      Co-Investigator
    • Science Leadership and Integration
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2009
      -
      Aug 2014
      Co-Investigator
    • A Systems Genetics Analysis of Cancer Risk, Progression and Therapeutic Response
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 1999
      -
      Mar 2014
      Co-Investigator
    • Program Project Grant
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2003
      -
      Aug 2010
      Co-Investigator
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 47
    Data provided by UCSF Profiles, powered by CTSI
    1. Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ. NPJ Breast Cancer. 2022 Jan 13; 8(1):6. View in PubMed
    2. Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, I-SPY 2 Trial Consortium, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022 01; 23(1):149-160. View in PubMed
    3. Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428. View in PubMed
    4. Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. NPJ Breast Cancer. 2021 Oct 05; 7(1):131. View in PubMed
    5. Gonzalez-Ericsson PI, Wulfkhule JD, Gallagher RI, Sun X, Axelrod ML, Sheng Q, Luo N, Gomez H, Sanchez V, Sanders M, Pusztai L, Petricoin E, Blenman KRM, Balko JM, I-SPY2 Trial Team. Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. Clin Cancer Res. 2021 Jul 27. View in PubMed
    6. View All Publications

     

    Site Directory
      X